All are true about ramelteon except
|A||Agonist at MT1 and MT2 receptors|
|B||Is a substrate of CYP1A2|
|C||Has high addiction liability|
|D||Approved for treatment of insomnia|
a. It is agonist of MT1 and MT2 melatonin receptors (in the suprachiasmatic nuclei)
b. It is metabolized by CYP1A2—interacts with microsomal enzyme inducers and inhibitors)
c. Its major adverse effects include dizziness, somnolence, fatigue and endocrine changes (decreased testosterone and increased prolactin)
d. It causes minimal rebound insomnia or withdrawal symptoms.
e. It has less addiction liability and is not a controlled substance.